Literature DB >> 30246635

The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury.

Yoshimasa Oyama1, Colleen Marie Bartman1, Jennifer Gile1, Daniel Sehrt1, Tobias Eckle1.   

Abstract

BACKGROUND: Recently, we identified the circadian rhythm protein Period 2 (PER2) in robust cardioprotection from myocardial ischemia (MI). Based on findings that perioperative MI is the most common major cardiovascular complication and that anesthetics can alter the expression of PER2, we hypothesized that an anesthesia mediated downregulation of PER2 could be detrimental if myocardial ischemia and reperfusion (IR) would occur. METHODS AND
RESULTS: We exposed mice to pentobarbital, fentanyl, ketamine, propofol, midazolam or isoflurane and determined cardiac Per2 mRNA levels. Unexpectedly, only midazolam treatment resulted in an immediate and significant downregulation of Per2 transcript levels. Subsequent studies in mice pretreated with midazolam using an in-situ mouse model for myocardial (IR)-injury revealed a significant and dramatic increase in infarct sizes or Troponin-I serum levels in the midazolam treated group when compared to controls. Using the recently identified flavonoid, nobiletin, as a PER2 enhancer completely abolished the deleterious effects of midazolam during myocardial IR-injury. Moreover, nobiletin treatment alone significantly reduced infarct sizes or Troponin I levels in wildtype but not in Per2-/- mice. Pharmacological studies on nobiletin like flavonoids revealed that only nobiletin and tangeritin, both found to enhance PER2, were cardioprotective in our murine model for myocardial IR-injury.
CONCLUSION: We identified midazolam mediated downregulation of cardiac PER2 as an underlying mechanism for a deleterious effect of midazolam pretreatment in myocardial IR-injury. These findings highlight PER2 as a cardioprotective mechanism and suggest the PER2 enhancers nobiletin or tangeritin as a preventative therapy for myocardial IR-injury in the perioperative setting where midazolam pretreatment occurs frequently. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  PER2; circadian; flavonoid; midazolam; nobiletin; perioperative myocardial ischemia.

Mesh:

Substances:

Year:  2018        PMID: 30246635      PMCID: PMC6318050          DOI: 10.2174/1381612824666180924102530

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  40 in total

1.  H(2)O(2) opens mitochondrial K(ATP) channels and inhibits GABA receptors via protein kinase C-epsilon in cardiomyocytes.

Authors:  Hong Yan Zhang; Bradley C McPherson; Huiping Liu; Timir S Baman; Peter Rock; Zhenhai Yao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-04       Impact factor: 4.733

2.  Desynchronization of daily rest-activity rhythm in the days following light propofol anesthesia for colonoscopy.

Authors:  G Dispersyn; Y Touitou; O Coste; L Jouffroy; J C Lleu; E Challet; L Pain
Journal:  Clin Pharmacol Ther       Date:  2008-09-17       Impact factor: 6.875

Review 3.  Circadian MicroRNAs in Cardioprotection.

Authors:  Yoshimasa Oyama; Colleen Marie Bartman; Jennifer Gile; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

4.  Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis.

Authors:  Xiaodong Ma; Munish Kumar; Saibyasachi N Choudhury; Lindsey E Becker Buscaglia; Juanita R Barker; Keerthy Kanakamedala; Mo-Fang Liu; Yong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-06       Impact factor: 11.205

5.  Characterization of sevoflurane effects on Per2 expression using ex vivo bioluminescence imaging of the suprachiasmatic nucleus in transgenic rats.

Authors:  Izumi Matsuo; Norio Iijima; Ken Takumi; Shimpei Higo; Satoko Aikawa; Megumi Anzai; Hirotaka Ishii; Atsuhiro Sakamoto; Hitoshi Ozawa
Journal:  Neurosci Res       Date:  2015-12-13       Impact factor: 3.304

6.  Differential expression of gamma-aminobutyric acid receptor A (GABA(A)) and effects of homocysteine.

Authors:  Neetu Tyagi; David Lominadze; William Gillespie; Karni S Moshal; Utpal Sen; Dorothea S Rosenberger; Mesia Steed; Suresh C Tyagi
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

7.  The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium.

Authors:  Jennifer Gile; Benjamin Scott; Tobias Eckle
Journal:  Crit Care Med       Date:  2018-06       Impact factor: 7.598

8.  CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury.

Authors:  David Köhler; Tobias Eckle; Marion Faigle; Almut Grenz; Michel Mittelbronn; Stefanie Laucher; Melanie L Hart; Simon C Robson; Christa E Müller; Holger K Eltzschig
Journal:  Circulation       Date:  2007-10-01       Impact factor: 29.690

9.  The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome.

Authors:  Baokun He; Kazunari Nohara; Noheon Park; Yong-Sung Park; Bobby Guillory; Zhaoyang Zhao; Jose M Garcia; Nobuya Koike; Cheng Chi Lee; Joseph S Takahashi; Seung-Hee Yoo; Zheng Chen
Journal:  Cell Metab       Date:  2016-04-12       Impact factor: 27.287

10.  Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia.

Authors:  Tobias Eckle; Katherine Hartmann; Stephanie Bonney; Susan Reithel; Michel Mittelbronn; Lori A Walker; Brian D Lowes; Jun Han; Christoph H Borchers; Peter M Buttrick; Douglas J Kominsky; Sean P Colgan; Holger K Eltzschig
Journal:  Nat Med       Date:  2012-04-15       Impact factor: 53.440

View more
  10 in total

Review 1.  Circadian-Hypoxia Link and its Potential for Treatment of Cardiovascular Disease.

Authors:  Colleen Marie Bartman; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

Review 2.  Circadian disruption and human health.

Authors:  Anna B Fishbein; Kristen L Knutson; Phyllis C Zee
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 19.456

3.  A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction.

Authors:  Jennifer Gile; Yoshimasa Oyama; Sydney Shuff; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

4.  Intense Light Pretreatment Improves Hemodynamics, Barrier Function and Inflammation in a Murine Model of Hemorrhagic Shock Lung.

Authors:  Yoshimasa Oyama; Sydney Shuff; Joseph K Maddry; Steven G Schauer; Vikhyat S Bebarta; Tobias Eckle
Journal:  Mil Med       Date:  2020-09-18       Impact factor: 1.437

Review 5.  Translating around the clock: Multi-level regulation of post-transcriptional processes by the circadian clock.

Authors:  Amber A Parnell; Aliza K De Nobrega; Lisa C Lyons
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

6.  Intense light as anticoagulant therapy in humans.

Authors:  Yoshimasa Oyama; Sydney Shuff; Pavel Davizon-Castillo; Nathan Clendenen; Tobias Eckle
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

7.  Extensive mitochondrial proteome disturbance occurs during the early stages of acute myocardial ischemia.

Authors:  Jie Wang; Jun He; Yucheng Fan; Fangjing Xu; Qian Liu; Ruhua He; Ru Yan
Journal:  Exp Ther Med       Date:  2021-11-25       Impact factor: 2.447

8.  Reversible dysregulation of renal circadian rhythm in lupus nephritis.

Authors:  Rakesh Mishra; Ramalingam Bethunaickan; Celine C Berthier; Zhengzi Yi; Joshua J Strohl; Patricio T Huerta; Weijia Zhang; Anne Davidson
Journal:  Mol Med       Date:  2021-09-06       Impact factor: 6.354

9.  PER2 Regulates Reactive Oxygen Species Production in the Circadian Susceptibility to Ischemia/Reperfusion Injury in the Heart.

Authors:  Yaqian Weng; Hui Li; Lin Gao; Wenjing Guo; Shiyuan Xu; Le Li
Journal:  Oxid Med Cell Longev       Date:  2021-10-08       Impact factor: 6.543

Review 10.  Targeting circadian PER2 as therapy in myocardial ischemia and reperfusion injury.

Authors:  Yoshimasa Oyama; Lori A Walker; Tobias Eckle
Journal:  Chronobiol Int       Date:  2021-05-25       Impact factor: 3.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.